Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2014

View Archived Issues

Development of a rapid MRR test for the detection of malaria

Opexa Therapeutics to target neuromyelitis optica

AstraZeneca presents novel TMK inhibitors with antibacterial activity

Asubio Pharma presents promising preclinical data for ASB-14780

S1P1 functional antagonist demonstrates utility for multiple sclerosis

Almirall discloses novel PI3Kdelta inhibitors

Novel BACE1 inhibitors reported by Pfizer

Bayer Schering Pharma synthesizes new Mnk1 inhibitors

New mutation in the NARS2 gene linked to OXPHOS deficiencies

High prevalence of p.R326Q mutation found in patients with beta-ureidopropionase deficiencies

Theravance reports topline results from dose-ranging phase IIb trial of TD-4208 in COPD

Invion reports data from first two dose cohorts in phase I/II trial of INV-103 in SLE

Momenta Pharmaceuticals exercises option to acquire antibodies from AnaptysBio

Spectrum Pharmaceuticals to advance SPI-2012 to phase III

New indication for Spiriva Respimat approved in Europe

Ophthotech achieves milestone under Fovista agreement with Novartis

PharmAthene and Nanotherapeutics form biodefense development alliance

C3 Jian completes phase II trial of C16G2

Theravance presents promising data for the heterodimer antibiotic TD-1607

Neurodyn Life Sciences reports phase Ia data for Memogain

Update on FDA orphan drug status designations

FDA approves Astute Medical's NephroCheck acute kidney injury test

NIAID contracts Emergent BioSolutions to develop dry formulation of anthrax vaccine

Hyperion Therapeutics terminates development of DiaPep277 following evidence of misconduct

FDA advisory committee votes against recommending approval of nebivolol/valsartan

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...